FDA grants approval to Boehringer-Lilly’s Jardiance for heart failure
The approval is based on results from the Phase III EMPEROR-Preserved clinical trial of a once-daily dose of 10mg empagliflozin.

The approval is based on results from the Phase III EMPEROR-Preserved clinical trial of a once-daily dose of 10mg empagliflozin.
Abbisko is eligible to receive up to $258m in milestone payments from Lilly.
The companies collaborated initially in 2019 to use AI and machine learning to develop new therapies for CKD and IPF.
Neurimmune will receive an upfront payment of $30m from Alexion.
The FDA accepted an sNDA, which is based on data from the Phase III trial of the therapy.
We've analysed 10 years' worth of clinical trials data from GlobalData to pick out key geographic trends.
ByMerck will gain rights to Acceleron’s lead therapy candidate, sotatercept, intended to treat pulmonary arterial hypertension.
According to the trial results, Jardiance reduces the risk of death or hospitalisation due to heart failure for diabetic and…
ByThank you for subscribing to Pharmaceutical Technology